Vemurafenib for BRAF V600-mutant erdheim-chester disease and langerhans cell histiocytosis analysis of data from the histology-independent, phase 2, open-label VE-BASKET study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • DNA, Neoplasm
  • Mutation
  • Neoplasms
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-akt
  • Pyrimidines
  • Pyrroles

abstract

  • In this study, vemurafenib had prolonged efficacy in patients with BRAF V600-mutant ECD and LCH and warrants consideration as a new standard of care for these patients.

publication date

  • March 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5844839

Digital Object Identifier (DOI)

  • 10.1001/jamaoncol.2017.5029

PubMed ID

  • 29188284

Additional Document Info

start page

  • 384

end page

  • 388

volume

  • 4

number

  • 3